US-based ophthalmic medical device firm Avedro has received approval from the South Korean Ministry of Food and Drug Safety (MFDS) for its KXL cross-linking system.

The KXL system, including the VibeX family of riboflavin formulations was developed to carry out Lasik Xtra and accelerated cross-linking for keratoconus and post-Lasik ectasia.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Lasik Xtra is a three minute procedure conducted in conjunction with standard Lasik. It restores biomechanical integrity and strength to the cornea after a Lasik procedure.

In order to achieve accelerated corneal cross-linking, Lasik Xtra combines riboflavin ophthalmic solution with UVA irradiation from the company’s KXL device.

"The KXL system, including the VibeX family of riboflavin formulations was developed to carry out Lasik Xtra and accelerated cross-linking for keratoconus and post-Lasik ectasia."

Clinic director of Eyereum Eye Clinic David Sung Yong Kang said: "Lasik Xtra offers the ability to ‘lock-in’ the treatment outcomes for both my Lasik and photorefractive keratectomy (PRK) patients, offering them additional peace of mind.

See Also:

"As one of the early users of the technology in Korea, I’m excited to offer this improved procedure to my patient.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"I’ve been asked to join the Avedro Medical Advisory Board and I’m looking forward to working with the Avedro team to develop new applications for corneal cross-linking."

Accelerated cross-linking has the ability to halt progression of the condition in the early stages, for keratoconus and ectasia patients.

The approval of KXL system is a result of the company’s two-year effort working with the South Korean Ministry of Food and Drug Safety.

Avedro CEO David Muller said: "Korea represents a significant market opportunity, with approximately 140,000 Lasik procedures performed annually.

"This approval allows us to continue to expand our footprint in Asia. We look forward to bringing Avedro’s new treatment options to doctors and patients in Korea."

The company’s KXL system and single dose pharmaceutical products are currently being used in three Phase III US clinical trials, involving more than 100 US clinical sites.